Patents by Inventor Narendra Kumar B. Patel

Narendra Kumar B. Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20220204511
    Abstract: The present teachings provide a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: November 8, 2021
    Publication date: June 30, 2022
    Applicant: UNIVERSITY HEALTH NETWORK
    Inventors: Radoslaw Laufer, Grace Ng, Sze-Wan Li, Heinz W. Pauls, Yong Liu, Narendra Kumar B. Patel
  • HPK1 INHIBITORS AND METHODS OF USING SAME
    Publication number: 20220002313
    Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as a checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
    Type: Application
    Filed: July 12, 2021
    Publication date: January 6, 2022
    Inventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
  • HPK1 inhibitors and methods of using same
    Patent number: 11059832
    Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: July 13, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
  • PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20210009595
    Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: May 21, 2020
    Publication date: January 14, 2021
    Inventors: Radoslaw Laufer, Grace Ng, Sze-Wan Li, Heinz W. Pauls, Yong Liu, Narendra Kumar B. Patel
  • HPK1 INHIBITORS AND METHODS OF USING SAME
    Publication number: 20200190104
    Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
    Type: Application
    Filed: December 6, 2019
    Publication date: June 18, 2020
    Inventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
  • Pyrazolopyrimidine compounds
    Patent number: 10570143
    Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 25, 2020
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • HPK1 inhibitors and methods of using same
    Patent number: 10501474
    Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 10, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
  • PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20190322669
    Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: October 24, 2019
    Inventors: Radoslaw Laufer, Grace Ng, Sze-Wan Li, Heinz W. Pauls, Yong Liu, Narendra Kumar B. Patel
  • Kinase inhibitors and method of treating cancer
    Patent number: 10358436
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 23, 2019
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20190040074
    Abstract: The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 9, 2018
    Publication date: February 7, 2019
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • Pyrazolopyrimidine compounds
    Patent number: 10167289
    Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: January 1, 2019
    Assignee: University Health Network
    Inventors: Radoslaw Laufer, Grace Ng, Sze-Wan Li, Heinz W. Pauls, Yong Liu, Narendra Kumar B. Patel
  • Pyrazolopyrimidine compounds
    Patent number: 10106545
    Abstract: The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 23, 2018
    Assignee: University Health Network
    Inventors: Yong Liu, Heinz W. Pauls, Radoslaw Laufer, Sze-Wan Li, Peter Brent Sampson, Miklos Feher, Grace Ng, Narendra Kumar B. Patel, Yunhui Lang
  • KINASE INHIBITORS AND METHOD OF TREATING CANCER
    Publication number: 20180282306
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Application
    Filed: February 22, 2018
    Publication date: October 4, 2018
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3?-indolin]-2?-ones
    Patent number: 10077255
    Abstract: The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: September 18, 2018
    Assignee: University Health Network
    Inventors: Graham Cumming, Narendra Kumar B. Patel, Bryan T. Forrest, Yong Liu, Sze-Wan Li, Peter Brent Sampson, Louise G. Edwards, Heinz W. Pauls
  • HPK1 INHIBITORS AND METHODS OF USING SAME
    Publication number: 20180179221
    Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).
    Type: Application
    Filed: June 23, 2016
    Publication date: June 28, 2018
    Inventors: Peter Brent Sampson, Narendra Kumar B. Patel, Heinz W. Pauls, Sze-Wan Li, Grace Ng, Radoslaw Laufer, Yong Liu, Yunhui Lang
  • SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONES
    Publication number: 20180105511
    Abstract: The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.
    Type: Application
    Filed: October 23, 2017
    Publication date: April 19, 2018
    Applicant: University Health Network
    Inventors: Graham Cumming, Narendra Kumar B. Patel, Bryan T. Forrest, Yong Liu, Sze-Wan Li, Peter Brent Sampson, Louise G. Edwards, Heinz W. Pauls
  • Kinase inhibitors and method of treating cancer
    Patent number: 9907800
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: March 6, 2018
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20170320881
    Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 9, 2017
    Inventors: Radoslaw Laufer, Grace Ng, Sze-Wan Li, Heinz W. Pauls, Yong Liu, Narendra Kumar B. Patel
  • Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3?-indolin]-2?-ones
    Patent number: 9796703
    Abstract: The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: October 24, 2017
    Assignee: University Health Network
    Inventors: Graham Cumming, Narendra Kumar B. Patel, Bryan T. Forrest, Yong Liu, Sze-Wan Li, Peter Brent Sampson, Louise G. Edwards, Heinz W. Pauls
  • Kinase inhibitors and method of treating cancer with same
    Patent number: RE47731
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: November 19, 2019
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel